<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-3-4-5">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>

			</div>

			<div class="slide-title red two-line">
				Eltrombopag in severe aplastic anaemia: <br />adverse events from clinical trials experience
			</div>


			<div class="content-container" style="overflow-y: scroll;-webkit-overflow-scrolling: touch;">

				<table class="red">
					<tr>
						<th>Adverse reaction<sup>1</sup></td>
						<th style="text-align:center">Eltrombopag (N=43), %</td>
					</tr>
					<tr class="odd">
						<td>Nausea</td>
						<td style="text-align:center">33</td>
					</tr>
					<tr>
						<td>Fatigue</td>
						<td style="text-align:center">28</td>
					</tr>
					<tr class="odd">
						<td>Cough</td>
						<td style="text-align:center">23</td>
					</tr>
					<tr>
						<td>Diarrhoea</td>
						<td style="text-align:center">21</td>
					</tr>
					<tr class="odd">
						<td>Headache</td>
						<td style="text-align:center">21</td>
					</tr>
					<tr>
						<td>Pain in extremity</td>
						<td style="text-align:center">19</td>
					</tr>
					<tr class="odd">
						<td>Pyrexia</td>
						<td style="text-align:center">14</td>
					</tr>
					<tr>
						<td>Dizziness</td>
						<td style="text-align:center">14</td>
					</tr><tr class="odd">
						<td>Oropharyngeal pain</td>
						<td style="text-align:center">14</td>
					</tr>
					<tr>
						<td>Febrile neutropenia</td>
						<td style="text-align:center">14</td>
					</tr>
					<tr class="odd">
						<td>Abdominal pain</td>
						<td style="text-align:center">12</td>
					</tr>
					<tr>
						<td>Ecchymosis</td>
						<td style="text-align:center">12</td>
					</tr>
					<tr class="odd">
						<td>Muscle spasms</td>
						<td style="text-align:center">12</td>
					</tr>
					<tr>
						<td>Transaminases increased</td>
						<td style="text-align:center">12</td>
					</tr>
					<tr class="odd">
						<td>Arthralgia</td>
						<td style="text-align:center">12</td>
					</tr>
					<tr>
						<td>Rhinorrhoea</td>
						<td style="text-align:center">12</td>
					</tr>
				</table>

			</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>GlaxoSmithKline. Eltrombopag tablets for oral use. Prescribing Information (draft). 2014</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Desmond R <i>et al. Blood</i> 2014;123:1818</span></li>
			</ul>

		</div>

		<div class="information-overlay overlay">

			<header>Eltrombopag in aplastic anaemia: adverse events from clinical trials experience</header>
				
			<ul>
				<li><span>In the single-arm, open-label trial, 43 patients with severe aplastic anemia received eltrombopag with 26% of patients treated for >6 months and 16% for >1 year<sup>1</sup></span>
					<ul>
						<li><span>The most common adverse reactions (â‰¥20%) were nausea, fatigue, cough, diarrhoea and headache</span></li>
					</ul>
				</li>
				<li><span>Patients also had bone marrow aspirates evaluated for cytogenetic abnormalities<sup>1</sup></span>
					<ul>
						<li><span>New cytogenetic abnormalities were reported in eight patients (19%) receiving eltrombopag<sup>2</sup></span>
							<ul>
								<li><span><li><span>Cytogenetic abnormalities reported included changes to chromosome 7, 8 and 13<sup>1,2</sup></span></li></span></li>
							</ul>
						</li>
					</ul>
				</li>
			</ul>

		</div>

		</div>
	</div>
</div>